News Breaks |
|
|
| February 12, 2013 |
| 11:01 EDT |  | A, LLY, PFE | Agilent's Dako to collaborate with Pfizer on companion diagnostics
Dako, an Agilent Technologies (A) company, announced today it has entered into a collaboration agreement with Pfizer (PFE) in the field of companion diagnostics. The agreement constitutes a legal framework for various collaboration projects between the two companies, covering research, development and commercialization as well as advisory services. Financial terms of the agreement were not disclosed. This news follows an earlier announcement from Dako introducing a master framework agreement between Dako and Eli Lilly (LLY). |
|
|
News For A;PFE;LLY From The Last 14 Days Check below for free stories on A;PFE;LLY the last two weeks. |
|
|
| May 17, 2013 |
| 11:59 EDT |  | A | Options with decreasing implied volatility: ILMN LO A HES INFY CSCO
|
|
| May 16, 2013 |
| 11:33 EDT | | A | Options with decreasing implied volatility: PANL CSC FTK A NVDA
 Subscribe for More Information |
|
| 08:55 EDT |  | PFE, LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 11:42 EDT | | A | High option volume stocks: WWAV VIPS SIAL AINV A
|
|
| May 14, 2013 |
| 16:26 EDT | | A | Agilent CEO sees 2H13 macroeconomic environment "challenging"
Subscribe for More Information |
|
| 16:12 EDT | | A | Agilent raises stock repurchase program to $1B
Subscribe for More Information |
|
| 16:11 EDT | | A | Agilent announces restructuring program, will reduce headcount by about 450
Agilent announced that it has initiated a targeted restructuring program that is expected to reduce Agilent's total headcount by approximately 450 regular employees, representing approximately 2% of its global workforce. The timing and scope of workforce reductions will vary based on local legal requirements. When completed, the restructuring program is expected to result in an approximately $50M reduction in annual operating expenses. |
|
| 16:09 EDT |  | A | Agilent sees FY13 adjusted EPS $2.70-$2.85, consensus $2.88
Subscribe for More Information |
|
| 16:08 EDT | | A | Agilent sees Q3 adjusted EPS 60c-64c, consensus 74c
Subscribe for More Information |
|
| 16:07 EDT | | A | Agilent raises stock repurchase program to $1B
Subscribe for More Information |
| |
| 16:07 EDT | | A | Agilent reports Q2 adjusted EPS 77c, consensus 67c
Reports Q2 revenue $1.73B, consensus $1.74B. |
|
| 15:30 EDT | | A | Notable companies reporting after market close
Subscribe for More Information |
|
| 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 15:21 EDT | | A | Agilent May volatility elevated flat into Q2 and outlook
Agilent December May call option implied volatility is at 67, June is at 32, August is at 29; compared to its 26-week average of 28 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on May 14. |
|
| May 10, 2013 |
| 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 12:31 EDT | | PFE | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 11:48 EDT |  | PFE, LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 09:21 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:08 EDT | | PFE | Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. |
| |
|
|
|
|
